triamcinolone acetonide - Profile

What are the generic drug sources for triamcinolone acetonide and what is the scope of patent protection?

Triamcinolone acetonide is the generic ingredient in twenty-seven branded drugs marketed by Abbvie, Chattem Sanofi, Astellas, Ivax Pharms, Delcor Asset Corp, Teva, Solvay, Actavis Mid Atlantic, Alkem Labs Ltd, Alpharma Us Pharms, Ambix, Chartwell Rx, Cosette, Encube, Fougera Pharms, Glenmark Pharms Ltd, Macleods Pharms Ltd, Micro Labs, Morton Grove, Norvium Bioscience, Padagis Us, Pharmaderm, Pharmafair, Strides Pharma, Sun Pharma Canada, Taro, Topiderm, Crown Labs, Savage Labs, Pacira Pharms Inc, Apothecon, Alembic, Amneal, Caplin, Dr Reddys, Eugia Pharma, Hikma, Long Grove Pharms, Mylan Labs Ltd, Parnell, Sandoz, Teva Pharms Usa, Watson Labs, Allergan, Harrow Eye, Beach Prods, Epic Pharma Llc, Pai Holdings Pharm, Pharmobedient, Quagen, Aurobindo Pharma Ltd, Extrovis, Glenmark Speclt, Padagis Israel, Senores Pharms, Cmp Pharma Inc, Rising, Sciegen Pharms, Lupin Atlantis, Sanofi Aventis Us, Apotex, Perrigo Pharma Intl, Sun Pharm Inds Inc, and Bausch And Lomb Inc, and is included in one hundred and forty-three NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Triamcinolone acetonide has one hundred and sixty-five patent family members in twenty-nine countries.

Summary for triamcinolone acetonide

International Patents:	165
US Patents:	8
Tradenames:	27
Applicants:	64
NDAs:	143

US Patents and Regulatory Information for triamcinolone acetonide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	AZMACORT	triamcinolone acetonide	AEROSOL, METERED;INHALATION	018117-001	Apr 23, 1982		DISCN	No	No
Chattem Sanofi	NASACORT	triamcinolone acetonide	AEROSOL, METERED;NASAL	019798-001	Jul 11, 1991		DISCN	No	No
Astellas	ARISTOCORT	triamcinolone acetonide	CREAM;TOPICAL	083017-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Astellas	ARISTOCORT	triamcinolone acetonide	CREAM;TOPICAL	083016-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Astellas	ARISTOCORT	triamcinolone acetonide	CREAM;TOPICAL	083015-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Astellas	ARISTOCORT A	triamcinolone acetonide	CREAM;TOPICAL	083017-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Astellas	ARISTOCORT A	triamcinolone acetonide	CREAM;TOPICAL	088818-001	Oct 16, 1984		DISCN	No	No

Expired US Patents for triamcinolone acetonide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chattem Sanofi	NASACORT ALLERGY 24 HOUR	triamcinolone acetonide	SPRAY, METERED;NASAL	020468-002	Oct 11, 2013
Abbvie	AZMACORT	triamcinolone acetonide	AEROSOL, METERED;INHALATION	018117-001	Apr 23, 1982
Harrow Eye	TRIESENCE	triamcinolone acetonide	INJECTABLE;INTRAVITREAL	022048-001	Nov 29, 2007
Delcor Asset Corp	KENALOG-H	triamcinolone acetonide	CREAM;TOPICAL	086240-001	Approved Prior to Jan 1, 1982
Abbvie	AZMACORT	triamcinolone acetonide	AEROSOL, METERED;INHALATION	018117-001	Apr 23, 1982
Chattem Sanofi	NASACORT ALLERGY 24 HOUR	triamcinolone acetonide	SPRAY, METERED;NASAL	020468-002	Oct 11, 2013
Chattem Sanofi	NASACORT ALLERGY 24 HOUR	triamcinolone acetonide	SPRAY, METERED;NASAL	020468-002	Oct 11, 2013

International Patents for triamcinolone acetonide

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2013109362
Japan	6247720
South Africa	201300831
South Korea	101927551
Hong Kong	1213192	用於在人類受試者中治療眼部疾病的方法和裝置 (METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISEASES IN HUMAN SUBJECTS)
China	101959519
European Patent Office	3721872	PROCÉDÉS POUR LE TRAITEMENT DE MALADIES OCULAIRES CHEZ DES SUJETS HUMAINS (METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS)

Investment Scenario and Fundamentals Analysis of Triamcinolone Acetonide

Last updated: February 19, 2026

What is the Current Market Position of Triamcinolone Acetonide?

Triamcinolone acetonide is a synthetic corticosteroid with anti-inflammatory and immunosuppressive properties. It is marketed globally for various dermatological, allergic, and respiratory conditions. The drug has been available for several decades, with formulations including injections, topical creams, and nasal sprays.

Market sales for triamcinolone acetonide reached approximately $1.2 billion in 2022, with steady annual growth of 3-5% driven by expanding indications and ongoing patent protections in key markets. Major manufacturers include Sandoz (Novartis), Teva Pharmaceutical Industries, and Mylan. It is often included in off-patent or generic drug portfolios, influencing pricing and market competition.

How Do Regulatory and Patent Landscapes Affect Investment?

Triamcinolone acetonide, patent expired in many regions by 2010. However, some formulations, such as long-acting injectable depots or combination products, remain under patent protection until 2024-2027. Regulatory approvals are stable in the U.S., EU, and emerging markets, with FDA and EMA approvals for various indications.

Key regulatory considerations:

• Generics: Significant generic competition impacts pricing and margins.
• New formulations: Patent protection for extended-release or combination therapies offers potential for premium pricing.
• Regulatory hurdles: Variability in approval requirements across regions affects market entry timing.

Investment in branded formulations is limited; most market growth relies on generic sales. Companies engaging in development must navigate complex patent landscapes and regulatory processes to sustain profitability.

What Are the Competitive Dynamics and Market Drivers?

The competitive landscape is characterized by:

• Price erosion: Due to a high number of generics, prices have declined 60-80% since patent expiry.
• Formulation innovation: Extended-release injectable forms and nasal sprays command higher prices and loyalty.
• Expanding indications: Use in dermatology for allergic skin conditions and in dentistry for inflammatory diseases broadens market potential.

Market growth drivers include rising prevalence of allergic and inflammatory diseases, increasing prescription rates in emerging markets, and demand for cost-effective treatment options. However, generic competition constrains profit margins, emphasizing the importance of formulation differentiation.

What Are the R&D and Commercialization Opportunities?

Limited pipeline development exists for triamcinolone acetonide due to its mature status. However, opportunities include:

• Developing new delivery mechanisms that improve bioavailability or reduce dosing frequency.
• Creating combination products that leverage synergistic effects.
• Entering emerging markets with tailored formulations.

Any R&D investment must balance the limited lifecycle remaining on patents and the competitive environment dominated by generics. Licensing deals and partnerships are common avenues for market expansion.

What Financial Considerations Should Investors Note?

Financial analysis indicates:

• Profit margins are under pressure owing to commoditization of the drug.
• Research and development costs are minimal compared to novel drug therapies.
• Pricing trends negatively impact revenue growth but improve volume sales.

Market margins for generic triamcinolone acetonide are typically 10-15%. Premium formulations can sustain margins of 20-25%. Overall, revenues are stable but growth is limited by generics.

Key Risks and Opportunities

Risks:

• Patent expiries in key markets reduce pricing power.
• Price competition from multiple generic manufacturers.
• Regulatory changes could hinder access in emerging markets.

Opportunities:

• Formulation innovations that extend product lifecycle.
• Strategic partnerships to expand geographic reach.
• Specialty indications where patent exclusivity might remain.

Key Takeaways

• The market is mature with heavy generic competition, limiting upside but providing cash flow stability.
• Patent protections for new formulations offer short-term premium opportunities.
• Investment should focus on niche formulations, regional growth, or licensing agreements.
• Market growth depends primarily on expanding indications and emerging-market penetration.
• Risks stem mainly from widespread generic competition and regulatory shifts.

FAQs

1. Is Triamcinolone Acetonide a good investment option now?
It offers stable cash flow but limited growth; suitable for income-focused portfolios rather than growth strategies.

2. How long are patents active for new formulations?
Patents for extended-release or combination products typically expire between 2024 and 2027.

3. What are the main competitors of Triamcinolone Acetonide?
Other corticosteroids, such as hydrocortisone and betamethasone, and different formulations of the same drug.

4. Are market prices likely to decline further?
Yes; high generic competition has already caused significant price erosion, though premium formulations maintain somewhat higher prices.

5. What regions offer the best growth prospects?
Emerging markets such as India, China, and Latin America offer growth opportunities due to the rising prevalence of inflammatory diseases and expanding healthcare access.

---

References

[1] IQVIA. (2022). Market Data on Corticosteroid Sales.
[2] FDA. (2023). Approved Formulations and Patent Status.
[3] EMA. (2022). Drug Approvals and Patent Expiry Information.
[4] MarketsandMarkets. (2023). Global Corticosteroids Market Report.
[5] Statista. (2022). Global Market Revenue for Triamcinolone and Related Drugs.